ARTL Artelo Bioscienceslimited data
Nasdaq · Health Care · Pharmaceutical Preparations
Artelo Biosciences (ARTL) is in ThetaGrade’s extended coverage. It does not have a House Rating; this is a fundamentals-only summary from SEC filings, compared with Health Care peers. There is not enough usable data to grade its fundamentals (no recent quarterly XBRL data; 1 of 7 factors have data). 14% of the method weight is backed by data.
Data as of .
Growth
no data| Revenue growth (TTM, YoY) | data gap |
| EPS growth (TTM, YoY) | data gap |
Profitability
no data| Operating margin (TTM) | data gap |
| Free-cash-flow margin (TTM) | data gap |
Balance sheet
Average| Net debt / EBITDA | data gap |
| Current ratio | Average |
| Interest coverage | data gap |
From the filings
- Net cash
Next earnings
No reliable estimate: only 4 earnings releases (Item 2.02 8-Ks matched to 10-Q/10-K) found. Check the company’s investor-relations page.
Why no House Rating
- price under $10
- market cap under $1B
House Ratings, Weekly Picks and the CSP screen cover the Tier 1 universe only. Methodology
Get rating changes in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium.
Educational summary from public SEC filings; not a House Rating and not financial advice. Sector: SIC 2834 (Pharmaceutical Preparations). Source: SEC EDGAR filings. Data as of 2026-10-21.